Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
Eli Lilly's experimental weight loss drug combination, EloraTZP, demonstrated a 23% reduction in body weight during a 48-week Phase 2 trial. The combination outperformed the company's existing blockbuster drug, tirzepatide, in patients with obesity and type 2 diabetes.
Why it matters
This development suggests significant advancements in pharmacological obesity treatments, potentially expanding the market for highly effective weight management therapies.
EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in…
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in